This collaboration, announced today, aims to bolster the production and supply security of Oral Polio Vaccines (OPV), a crucial step towards achieving a polio-free world.
As per Bharat Biotech, MTBVAC is the first vaccine against Tuberculosis derived from a human source by the Spanish biopharmaceutical company, Biofabri.
Dr Krishna Ella, Executive Chairman at Bharat Biotech, expressed enthusiasm about the agreement, stating, "This agreement reflects our ethos to facilitate collaborative research, foster innovation, and further advance the science vaccine technology".
Bharat Biotech is a world-leading vaccine and biotherapeutics manufacturer. During the Covid pandemic, it made the vaccine Covaxin, which was administered by millions across the globe
Speaking on the importance of health to ANI, Krishna Ella said, "I'm happy that we are having G20 in Hyderabad. Number one, the government of India is talking about digital health and everybody is now agreeing digital health is very important. Our Prime Minister's vision to have digital heal
"It's easy to deliver and doesn't need any syringe or needle and most important it produces three immune responses, IgG, IgA, & T cell response. No other vaccine in the world can produce three responses," said Dr Krishna Ella, Chairman & MD, Bharat Biotech on the launch of the 'iNCOV
Mandaviya unveiled the Inncovacc- the first India-made nasal Covid-19 vaccine today in the presence of Union Minister of State (IC) for Science and Technology, Jitendra Singh.
As the country's marked its 74th Republic Day, Union Health Minister Dr Mansukh Mandaviya and Union Science and Technology Minister Jitendra Singh launched Bharat Biotech's first India-made nasal Covid-19 vaccine, iNCOVACC, on Thursday.